NEW YORK (360Dx) – Nightingale Health announced on Monday that its blood analysis biomarker system has received CE marking for the measurement of creatinine and glucose.
The Finnish company's system is based on nuclear magnetic resonance spectroscopy, and is designed to capture and analyze over 228 metabolic biomarkers from a single blood sample. The technology has previously been available for research use only to assess a patient's risk for developing diabetes and cardiovascular disease.
Nightingale said that it aims to introduce dozens of the other biomarkers analyzed by its system for clinical use within the next year.
"We expect a rapid entry to the clinical market across Europe," Nightingale Cofounder and CEO Teemu Suna said in a statement. "We believe that our technology takes us one step closer to better prevention of chronic diseases."
Earlier this year, Suna said that Nightingale's technology may have diagnostic applications in brain-related illnesses, and that the firm plans to seek US Food and Drug Administration approval for its system in the future.